Abstract
Purpose: Growing evidence implies that selenium and vitamin E may decrease the risk of prostate cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a randomized prospective double-blind study designed to determine whether selenium and vitamin E decrease the risk of prostate cancer in healthy men. Materials and Methods: The preclinical and epidemiological evidence regarding chemoprevention with selenium and vitamin E were reviewed. Secondary analyses from randomized trials of the 2 agents were included in the current analysis. Data from these analyses as well as evidence from the Prostate Cancer Prevention Trial were used to develop the SELECT schema. Results: Preclinical, epidemiological and phase III data imply that selenium and vitamin E have potential efficacy for prostate cancer prevention. The experience of the Prostate Cancer Prevention Trial shows the interest and dedication of healthy men to long-term studies of cancer prevention. A total of 32,400 men are planned to be randomized in SELECT. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment in the study is planned to begin in 2001 with final results anticipated in 2013.
Original language | English (US) |
---|---|
Pages (from-to) | 1311-1315 |
Number of pages | 5 |
Journal | Journal of Urology |
Volume | 166 |
Issue number | 4 |
DOIs | |
State | Published - Jan 1 2001 |
Keywords
- Chemoprevention
- Prostate
- Prostatic neoplasms
- Selenium
- Vitamin E
ASJC Scopus subject areas
- Urology